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EgyptAbstract Rheumatic fever (RF) and rheumatic heart disease (RHD) have decreased in prevalence
in the advanced industrialized nation. In the developing world, RF and RHD although less preva-
lent than they were 30 to 50 years ago, are still a major health problem. Poor socio-economic stan-
dards and difﬁculty of reaching proper primary health care facilities are the main causes of the still
relatively high prevalence. This article will discuss in brief the epidemiology of group A beta hemo-
lytic streptococci (GAS) and RF/RHD as well as their global burden. The gloomy past of RF/RHD
will hopefully give way to the promising future we all strive to achieve through better social stan-
dards, sanitation and hygiene, and availability of better health care for all.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction and deﬁnition
Rheumatic fever (RF) is a non-suppurative sequel of Group A
beta hemolytic streptococcal infection of the upper respiratory
tract due to a delayed immune response. It affects mainly chil-
dren and young adults in their most productive years.
Studies done with the WHO (World Health Organization)
have clearly shown that a proper primary health care and sec-ondary prevention program are both cost effective and inex-
pensive and hence reduce the burden of disease.1–3
Despite the documented decrease in the incidence of acute
rheumatic fever and prevalence of rheumatic heart disease
(RHD), it still is an important cause of cardiovascular disease
worldwide. Heart valve surgery adds to the lifelong burden of
disease.
2. Epidemiology of group A streptococci, rheumatic fever and
rheumatic heart disease
2.1. Group-A streptococcal infections
There are several groups of beta hemolytic streptococci
depending on their cell-wall polysaccharide antigens. Serolog-
ical group-A beta hemolytic streptococci (GAS) can again be
divided into more than 130 different M-types responsible for
most human infections; mainly pharyngitis and impetigo.
Pharyngitis caused by group-A streptococci is related to the
pathogenesis of rheumatic fever and rheumatic heart disease
Table 1 Examples of reported prevalence of rheumatic heart disease in school children.
WHO Region (country, city) Year Rate/1000 population
Africa
Kenya (Nairobi) 1994 2.7
Zambia (Lusaka) 1986 12.5
Ethiopia (Addis Ababa) 1999 6.4
Guinea (Conakry) 1992 3.9
DR Congo (Kinshasa) 1998 14.3
Americas
Cuba (Havana, Santiago, P. del Rio 1987 0.2–0.9
Bolivia (La Paz) 1986–1990 7.9
Eastern Mediterranean
Morocco 1989 3.3–10.5
Egypt (Cairo) 1986–1990 5.1
Sudan (Khartoum) 1986–1990 10.2
Saudi Arabia 1990 2.8
Tunisia 1990 3–6
South East Asia
Northern India 1992–1993 1.9–4.8
India 1984–1995 1–5.4
Nepal (Katmandu) 1997 1.2
Sri Lanka 1998 6
Western Paciﬁc
Cook Islands 1982 18.2
French Polynesia 1985 8
New Zealand (Hamilton) 1983 6.5 (Maoris)
0.9 (Non-M)
Samoa 1999 77.8
Australia (Northern Territory) 1989–1993 9.6
Multiple sources quoted from: WHO Expert Consultation on Rheumatic Fever and Rheumatic Heart Disease, Geneva 29/10–1/11 2001.
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20% of pharyngitis in children is caused by GAS and the
remaining 80% are viral.1,5–7
The incidence of GAS pharyngeal infections varies between
countries and also within the same country depending on sev-
eral factors including season (usually winter), age group, socio-
economic conditions, environmental conditions and level of
primary health care.1,4,5,8–10 GAS carrier rates occur from
10% to 50% of asymptomatic school children.1,8 Only in the
true infection does the patient show a rising antibody titer.
Probably those with true infections are the ones who develop
RF and can also spread the pharyngeal infections.
GAS pharyngeal infection can be easily transmitted and spread
rapidly in families and among school children; pointing to the del-
eterious effects of overcrowded living conditions and school class-
rooms as an important cause of the spread of GAS pharyngitis.
3. Rheumatic fever and rheumatic heart disease
Data on the incidence of RF are difﬁcult to obtain. In some
countries, mostly the more developed nations, the incidence
from RF registers of school children has shown a wide varia-
tion between countries. The developed countries show an inci-
dence of below 1 in 100,000.12 Others from developing
countries vary from 1 per 100,000 in Costa Rica,11 100 per
100,000 in the Sudan.12
The prevalence of RHD is better studied by different coun-
tries mainly of school-age children. It varied widely betweencountries (Table 1) and even between different ethnic groups
in the same country during the last 10 years of the last century.
It is noticed that the prevalence varies from 0.2 per 1000 school
children in Havana, Cuba to 77.8 per 1000 in Samoa.
Several developing countries have implemented prevention
programs and hence a marked decrease occurred in the inci-
dence of RF and RHD. Examples are Cuba, Costa Rica and
Egypt.11–13
Multiple sources quoted from: WHO Expert Consultation
on Rheumatic Fever and Rheumatic Heart Disease, Geneva
29/10–1/11 2001.18
4. The global burden of RHD
In developing countries, RF and RHD have been estimated to
affect nearly 20 million people.14 There are 470,000 new cases
of RF and 233,000 deaths due to RF and RHD worldwide
annually.15 Out of the 20 million, about 3–4 million have con-
gestive heart failure (CHF) that require repeated hospital
admissions with a large number of these requiring heart valve
surgery within 5–10 years.12,16,17 The mortality rate varies
from 1.8/100,000 in the WHO region of the Americas to 7.6/
100,000 in the WHO region of South-East Asia.
Another way to estimate the effect of the disease is by using
the disability adjusted life years lost (DALYs). This is deﬁned
as the sum of years of life lost owing to premature death, plus
the years lived with disability adjusted for the severity of the
disability17 (Table 218).
Table 2 Estimated deaths and DALY’s lost to rheumatic heart disease in 2000, by WHO region.18.
WHO Region Deaths DALY’s* lost
N (·103) Rate (per 100000 Population) n (·106) Rate (per 100000 Population)
Africa 29 4.5 0.77 119.8
The Americas 15 1.8 0.24 27.4
East. Med. 21 4.4 0.59 121.6
Europe 38 4.3 0.49 56.1
SE Asia 117 7.6 2.66 173.4
West. Paciﬁc 115 6.8 1.78 105.4
World 332 5.5 6.63 109.6
* DALY’s: disability-adjusted life years.
Figure 1 The decline in rheumatic fever started at the beginning of 20th century long before introduction of effective drug
penicillin21.
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It was not long ago (1950’s) when rheumatic fever and rheu-
matic heart disease were rampant in Egypt and other develop-
ing countries around the world at a time when the more
developed industrial nations were showing a deﬁnite decline
in their incidence and prevalence. Let us look back at the
1950’s when it was reported - in a ﬁeld study of a populous
area – that the prevalence of rheumatic heart disease was as
high as 1000/100,000 population.19 Overcrowded homes and
schools were part of daily life. In the 1980’s, a school survey
showed a deﬁnite improvement (190/100000) but still a high
prevalence compared to advanced nations.20
5.1. A socio-economic disease
If we look back at the history of RF/RHD from the early years
of the 1900’s when rheumatic fever was devastating, it becomes
very clear that the incidence started to drop early before the
onset of antibiotics (Fig. 1)
A combination of low socio-economic status, overcrowd-
ing, poor sanitary conditions, poor nutrition and the absence
of medical services all helped in bringing about the high prev-
alence of RF/RHD. With improvement of some or all of these
factors this high prevalence started to decline even before the
mass introduction of penicillin in 1948. After penicillin a pre-
cipitous fall of the incidence of RF/RHD occurred.
The World maps in Fig. 2 show the prevalence spanning 4
decades. Clearly seen is the very high prevalence from 1970 to1990. A signiﬁcant drop occurred from 1990 to the present and
is still improving.6. The promising future
With the political changes occurring throughout the region as
well as Egypt, it is hoped that the socio-economic standard and
the quality of life will improve. This will be translated into bet-
ter sanitary conditions and housing, healthier schools and bet-
ter availability of primary health care in all regions of the
country.
There is a deﬁnite decline in the prevalence of RF/RHD in
Egypt since the middle of the last century. With the expected
changes of the socio-economic structure and medical care in
the near future; we expect to see a further decline in their prev-
alence. Reaching the prevalence seen in developed countries
now seems more attainable than was felt.7. Conclusion
RF/RHD is a disease of low and middle income countries.
Unfortunately the disease affects young adults in their most
productive years; adding to the economic burden of the in-
volved families and the nation as a whole.
In the 1950’s and 60’s, RF/RHD was rampant. A slow and
steady decline in their prevalence has occurred since then; but
not reaching the ideal goals. With the expected improvement in
the socio-economic standards and primary and school health,
Figure 2 Maps showing difference in the prevalence of RHD at
two different periods22.
142 K.A. Soroura further decline is expected, reaching the prevalence seen in
high income countries within the next 2 decades.
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